Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSE-279 in Advanced Solid Tumors or Lymphomas
NCT05751798Phase 2Recruiting
- Sponsor
- OSE Immunotherapeutics
- Start
- Dec 2022
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of OSE-279 in solid tumor, lymphoma, non-small cell lung cancer (NSCLC), sponsored by OSE Immunotherapeutics. Started Dec 2022; status: recruiting.
02
Drugs
OSE-279
03
Conditions
solid tumorlymphomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05751798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751798.